Annual report and full year financial results

Aug 21st, 2018

Melbourne, Australia: Starpharma today released its annual report and financial results for the year ended 30 June 2018.

Read More

Quarterly Cashflow Report

Jul 17th, 2018

Melbourne, Australia; Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2018.

Read More

VivaGel® BV NDA advances to next stage of FDA review

Jul 9th, 2018

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that the US FDA has completed its filing review of the VivaGel^® BV New Drug Application (NDA), with no issues identified, and confirmed its progress to the next stage.

Read More

Starpharma licenses VivaGel® BV to Mundipharma for Europe

Jun 27th, 2018

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) and Mundipharma today announced they have signed a licence agreement for the sales and marketing rights to VivaGel®BV for 43 countries in Europe, Russia, the Commonwealth of Independent States (CIS) and the balance of countries in Latin America. This deal builds on the VivaGel® BV licence signed with Mundipharma in May 2018 for Asia, the Middle East, Africa and parts of Latin America. 

Read More

Starpharma CEO Dr Jackie Fairley interviewed by Alan Kohler for The Constant Investor

Jul 16th, 2018

Starpharma CEO Dr Jackie Fairley speaks with Alan Kohler on online investor publication The Constant Investor, where she discussed the company’s dendrimer platform technology. To listen to fully interview, click here. (Note: paywall) Read More

Starpharma CEO Dr Jackie Fairley interviewed by Alan Kohler on Talking Business

Jul 1st, 2018

To listen to the podcast, click here.

Read More

Starpharma CEO Jackie Fairley featured on Qantas’ inflight magazine Travel Insider

Jul 1st, 2018

Starpharma CEO Dr Jackie Fairley was featured in Qantas’ inflight magazine. To read the article, click here.

Read More

Starpharma on CommSec’s The Executive Series

Mar 14th, 2018

Read More

Shareholder Update February 2018

Feb 19th, 2018

In this issue: 

>> New sites open for the DEP^® docetaxel phase 2 trial

>> DEP^® cabazitaxel phase 1 / 2 trial commences

>> VivaGel^® BV NDA submission lodged under Fast Track program

>> VivaGel^® BV approved by TGA

>> DEP^® irinotecan progressing towards the clinic

>> AstraZeneca-Starpharma collaboration

>> Extensive global licensing negotiations for VivaGel^® BV

>> Positive market research findings for VivaGel^® BV 

>> Q2 Cashflow Report at 31 December 2017

>> OTCQX market recognition

>> Starpharma News & Events

>> Outlook

 Download: Shareholder Update February 2018 (pdf file, 1.5mb)

Read More

Shareholder Update October 2017

Oct 18th, 2017

In this issue: 

>> DEP^® docetaxel achieves positive phase 1 results and commences phase 2

 >> AZ presents first DEP^® candidate AZD0466 – a Bcl2/xL inhibitor

>>  Successful VivaGel^® BV phase 3 results

>> Update on other internal DEP^® candidates

>> Grant awarded to Starpharma-Monash

>> Starpharma and Peter Mac Cancer Centre awarded grant

>> FY17 Financial results; >$60M cash at 30 June

>> Annual Report and Annual General Meeting

>> Starpharma News & Events

 

Download: Shareholder Update October 2017 (pdf file, 1.3mb)

Read More